Endologix Inc. (ELGX)
-NasdaqGS 14.00 
0.31(2.17%) 2:22PM EDT - Nasdaq Real Time Price
| Prev Close: | 14.31 |
|---|
| Open: | 14.40 |
|---|
| Bid: | 14.01 x 200 |
|---|
| Ask: | 14.03 x 100 |
|---|
| 1y Target Est: | 17.50 |
|---|
| Beta: | 0.94 |
|---|
| Next Earnings Date: | 22-Jul-13 |
|---|
| Day's Range: | 14.00 - 14.50 |
|---|
| 52wk Range: | 11.15 - 16.39 |
|---|
| Volume: | 259,943 |
|---|
| Avg Vol (3m): | 424,392 |
|---|
| Market Cap: | 879.17M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.47 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Here's Why Endologix's Latest Report Might Worry Youat Motley Fool(Wed 1:04AM EDT)
- Finding Value in the Medical Products and Device Spaces: An Experienced Portfolio Manager Discusses Investing in Overlooked Health Care AreasWall Street Transcript(Fri, May 17)
- Here's 1 Reason Endologix Looks Weakat Motley Fool(Mon, May 13)
- ENDOLOGIX INC /DE/ FinancialsEDGAR Online Financials(Fri, May 10)
- Endologix to Participate in Three Upcoming Investor ConferencesGlobeNewswire(Wed, May 8)
- Is a Revenue Miss Coming for Endologix?at Motley Fool(Wed, May 8)
- ENDOLOGIX INC /DE/ Files SEC form 10-Q, Quarterly ReportEDGAR Online(Mon, May 6)
- Endologix Earnings: Here’s Why Investors are Ambivalent Nowat Wall St. Cheat Sheet(Tue, Apr 30)
- Endologix's CEO Discusses Q1 2013 Results - Earnings Call Transcriptat Seeking Alpha(Tue, Apr 30)
- Endologix Reports 22% Revenue Growth for the First Quarter 2013GlobeNewswire(Tue, Apr 30)
- ENDOLOGIX INC /DE/ Files SEC form 8-K, Results of Operations and Financial ConditionEDGAR Online(Tue, Apr 30)
- Q1 2013 Endologix Inc. Earnings Release - After Market CloseCCBN(Tue, Apr 30)
- ELGX Crosses Below Key Moving Average Levelat TheStreet(Thu, Apr 18)
- Endologix Announces FDA Approval of First Percutaneous Indication for Endovascular Abdominal Aortic Aneurysm RepairGlobeNewswire(Tue, Apr 16)
- Endologix Board Member Roderick de Greef to Retire; Thomas F. Zenty, III to Stand for Election as Board MemberGlobeNewswire(Mon, Apr 15)
Key Statistics
| Forward P/E (1 yr): | 127.36 |
|---|
| P/S (ttm): | 8.08 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.16 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.05 |
|---|
| Mean Recommendation*: | 1.5 |
|---|
| PEG Ratio (5 yr expected): | -0.93 |
|---|
Business Summary
Endologix, Inc. develops, manufactures, markets, and sells medical devices for the treatment of aortic disorders. It offers the ELG System, a stent graft and delivery system for the treatment of abdominal aortic aneurysms through minimally-invasiv...
View More